Merck KGaA Drug Fails in Late-Stage Brain Cancer Trial

Merck KGaA’s experimental tumor-fighting drug cilengitide failed to help patients with a form of brain cancer in a late-stage clinical trial, adding to recent drug-development setbacks for the company.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.